ABBV insider buying and SEC filings, explained
AbbVie Inc. · CIK 1551152
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Company profile
- Exchanges
- NYSE
- Industry (SIC)
- Pharmaceutical Preparations
- State of incorporation
- DE
- Fiscal year end
- Dec 31
Insider activity in the last 12 months
Bought
$0
Insiders who bought
0
Sold (not marked 10b5-1)
$1.2M
Planned sales (10b5-1)
$9.5M
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| Mar 4, 2026 | Sale | David Ryan Purdue (SVP, Controller) sold 5,230 shares at $233.56 ($1.2M). Holdings down 66% to 2,654 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 6, 2026 |
| Mar 2, 2026 | Planned (10b5-1) | Perry C Siatis (EVP, GC and Secretary) sold 18,668 shares at about $234.39 ($4.4M), marked as a 10b5-1 plan trade. Holdings down 80% to 4,619 shares. | SEC filing Filed Mar 3, 2026 |
| Feb 25, 2026 | Planned (10b5-1) | Perry C Siatis (EVP, GC and Secretary) sold 22,381 shares at $230.00 ($5.1M), marked as a 10b5-1 plan trade. Holdings down 37% to 38,137 shares. | SEC filing Filed Feb 27, 2026 |
42 routine transactions (such as grants, option exercises or tax withholding) are not listed.
Cluster buys
No cluster buys in the last 12 months.
Red flags
No red flags in the last 12 months.
Key events
| Tag | Items | Filed | Source |
|---|---|---|---|
| CEO departure Detected from the filing text | 8-K Item 5.02 | Nov 2, 2026, 4:05 PM ET | SEC filing |
8-K filings, last 12 months
| Filed | Items | Tag | Source |
|---|---|---|---|
| Nov 2, 2026, 4:05 PM ET 8-K | Executive or director change (Item 5.02) | CEO departure Detected from the filing text | SEC filing |
| Oct 30, 2026, 7:51 AM ET 8-K | Earnings released (Item 2.02) | SEC filing |
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow ABBV in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.